Despite nearly two decades of research investigating the use of dietary antioxidant supplementation during conventional chemotherapy and radiation therapy, controversy remains about the efficacy and safety of this complementary treatment. Several randomized clinical trials have demonstrated that the concurrent administration of antioxidants with chemotherapy or radiation therapy reduces treatment-related side effects. Some data indicate that antioxidants may protect tumor cells as well as healthy cells from oxidative damage generated by radiation therapy and some chemotherapeutic agents. However, other data suggest that antioxidants can protect normal tissues from chemotherapy-or radiation-induced damage without decreasing tumor control. We review some of the data regarding the putative benefits and potential risks of antioxidant supplementation concurrent with cytotoxic therapy. On the basis of our review of the published randomized clinical trials, we conclude that the use of supplemental antioxidants during chemotherapy and radiation therapy should be discouraged because of the possibility of tumor protection and reduced survival.
Physicians must abide by the dictum primum non nocere, that is, "first, do no harm." This tenet is central to the practice of medicine and serves as the foundation for medical treatments and therapeutic recommendations. At the earliest indication that a specific therapy may be harmful to a patient, a physician is obligated to assess the evidence about whether the putative benefit outweighs the potential harm. In the absence of good evidence of benefit, it is contrary to the principle of primum non nocere to advise patients to continue a potentially harmful intervention.
What, then, should physicians tell their patients about the use of supplemental antioxidants during chemotherapy and radiation therapy? Several clinical studies ( 1 -6 ) have reported modest decreases in treatment-related side effects when supplemental antioxidants -either dietary or pharmaceutical -are administered concurrently with cytotoxic regimens. However, concern has been expressed ( 7, 8 ) that the action of supplemental antioxidants might not be restricted to reducing the oxidative damage to normal tissues generated by radiation therapy and certain chemotherapeutic agents. Theoretically, antioxidants can exert their effects on all tissues to some degree, thereby protecting tumor cells as well as healthy ones. Experimental and clinical studies ( 5 , 6 , 9 -16 ) lend support to this hypothesis, with some clinical data also suggesting that cancer patients who use antioxidant supplements during radiation or chemotherapy have worse survival than those who do not ( 5 , 6 , 14 , 17 ) . Here, we present the available data on the use of supplemental antioxidants during chemotherapy or radiation therapy and highlight the reasons why this combined treatment approach should be avoided until it is shown to be safe.
Effects of Oncological Treatment and Mechanisms of Action of Antioxidants
The principal therapeutic effect of radiation occurs indirectly via the ionization of water molecules in the cytoplasm to reactive oxygen species, for example, superoxide and hydroxyl radicals.
These free radicals react with nuclear DNA, thereby creating structural bonds that are potentially fatal to cells. Some of this radiation damage can be repaired, leaving a cell that remains viable and that can proliferate. It takes only a millisecond for the free radical -DNA reaction to occur, and a normal cell that is not killed outright can repair the damage in as few as 6 hours ( 18 ) . Antioxidants are compounds that can counteract free radicals and prevent them from causing tissue and organ damage ( 19 ) . They function through a variety of mechanisms: as preventative agents that suppress the formation of free radicals, as radical scavenging agents that inhibit chain initiation and/or propagation, as repair and de novo enzymes that repair and reconstitute cell membranes, and as adaptation agents that generate appropriate antioxidant enzymes and transfer them to the necessary site of action ( 20 ) . Antioxidants -whether produced endogenously (eg, ␣ -lipoic acid, ubiquinone) or consumed in the diet (eg, ␣ -tocopherol, ascorbic acid) -must be present in the cell during the free radical -DNA reaction, and at a sufficient concentration, to be effective in blocking free radical -mediated DNA damage. Although antioxidants, by definition, scavenge free radicals, it is important to recognize that most also act via other mechanisms to affect cell proliferation, apoptosis, angiogenesis, and other processes relevant to tumor growth and metastasis ( 21 ) ( Table 1 ) .
Although antioxidants may play a role in the primary prevention of cancer in part by reducing the oxidative modifi cation of DNA ( 22 ) , the same action might be expected to be counterproductive against radiation therapy and chemotherapeutic agents that act solely via the production of reactive oxygen species and induction of apoptosis ( 19 ) . These agents include the anthracyclines (eg, doxorubicin), platinum-containing complexes (eg, cisplatin, carboplatin), alkylating agents (eg, cyclophosphamide, ifosfamide), and cytotoxic antibiotics (eg, bleomycin, mitomycin-C). Dietary antioxidants comprise a variety of chemical classes, including carotenoids, polyphenols, tocols, and triterpenes, and they display an array of biologic activities. Thus, it is not possible to make broad generalizations about whether or how they might interact with oncological treatments. Nonetheless, these nutrients are defi ned by their shared capacity for quenching reactive oxygen and nitrogen species even though their in vivo potency and selectivity can vary substantially by class, bioavailability, dose, and duration, as well as by route of administration ( 19 ) . For example, the most readily bioavailable form of the antioxidant lycopene is in cooked rather than raw foods, and ascorbic acid acts as an antioxidant when taken orally but as a prooxidant when administered intravenously at high doses ( 19 , 23 ) . Individual variations (eg, polymorphisms) in the expression of antioxidant enzymes such as superoxide dismutase and catalase further complicate potential interactions between oncological treatments and the antioxidant defense network. For example, some polymorphisms in the gene encoding glutathione-S -transferase, an antioxidant enzyme, can decrease the antioxidant activity of the enzyme ( 24 , 25 ) .
In discussions of antioxidant supplementation, one must distinguish between high-dose antioxidant supplementation and supportive dietary antioxidant supplementation (ie, low-dose dietary intakes to support normal function through the intake of the essential vitamins C and E and the other antioxidants found in plant foods). In addition, it is important to recognize that when specifying doses of an antioxidant, the matrix and mix of isomeric compounds can differ markedly between foods and supplements. Laboratory evidence indicates that the effect of dietary antioxidants on tumors is dose dependent. In the absence of radiotherapy or chemotherapy, high doses of dietary antioxidants often inhibit the growth of cancer cells without affecting the growth of normal cells ( 26 -28 ) . However, data from some studies indicate that antioxidant supplementation at doses that are intermediate to dietary intakes (relatively low doses) and high supplemental doses may reduce the effi cacy of x-irradiation against cancer cells ( 10 , 12 ) or stimulate tumor cell growth (29) . Interpretation of these experimental data is diffi cult because the doses that inhibit tumor cell growth vary between species and tumor types and the distribution of antioxidants varies between tumor cells and normal cells ( 29 , 31 -36 ) .
The above-mentioned variables (eg, high-dose vs relatively low-dose antioxidant supplementation, variations in antioxidant classes) may substantially defi ne the effi cacy and safety profi les of specifi c antioxidant supplements as therapy for cancer patients receiving selected chemotherapy agents or radiation therapy. Recommendations about the use of specifi c antioxidant supplements during radiation or chemotherapy can be established only after further clinical studies have evaluated these and other variables (eg, tumor and normal tissue protective effects at different antioxidant dose levels and mixtures of antioxidants ).
Radiation Therapy and Antioxidants
We attempted to identify all published randomized clinical trials that have investigated the possible radiomodifying effects (ie, increasing or decreasing radiosensitivity) of concurrent administration of supplemental antioxidants on normal tissues and tumors by searching the Medline database with the following key words: radiation therapy, cancer, tumor control, side effects, toxicity, vitamins, and antioxidants (see Table 2 ).
Bairati et al. ( 5 , 37 ) reported that among 540 head and neck cancer patients who were randomly assigned to receive either ␣ -tocopherol with or without ␤ -carotene vs placebo concurrent with their radiation therapy, those who received both antioxidants had a statistically signifi cant 38% reduction in severe, acute side effects. However, this benefi t appeared to be offset by reductions of 29% and 56% in the local tumor control rates for ␣ -tocopherol and ␣ -tocopherol plus ␤ -carotene, respectively. It is interesting to note that in a recently reported subgroup analysis of these patients ( 38 ) , the interactions between antioxidant supplementation and cigarette smoking during radiation therapy were associated with an increase in both disease recurrence (hazard ratio [HR] = 2.41, 95% confi dence interval [CI] = 1.25 to 4.64) and cancer-specifi c mortality (HR = 3.38, 95% CI = 1.11 to 10.34). There was no increase in either of these outcome measures for the nonsmokers. The most concerning data are presented in a subsequent publication by Bairati et al. ( 17 ) on the same cohort of patients. In this article, they demonstrate that the patients who received antioxidants had statistically signifi cant poorer overall survival.
Relatively few randomized controlled trials of antioxidants and radiation therapy, such as those carried out by Bairati et al. ( 5 , 17 , 37 ) , are available. Because of the reasonably large sample size * po = orally; OR = odds ratio; CI = confidence interval; HR = hazard ratio; RTOG = Radiation Therapy Oncology Group; EORTC = European Organization for
Research and Treatment of Cancer; OS= overall survival; TID = three times per day; BID = two times per day; OS1 = overall survival at 1 year; OS2 = overall survival at 2 years; PFS = progression-free survival; PFS1 = progression-free survival at 1 year; PFS2 = progression-free survival at 2 years; XRT = radiation therapy; LRF = local regional failure; NS = not statistically significant; IV = intravenous injection; SC = subcutaneous injection; RR = relative risk. † Comments: 1) logistic support for the meta-analysis was provided by Schering -Plough; 2) 7 of the 14 included studies were documented to have pharmaceutical sponsorship; 3) seven trials did not state their sponsorship. ‡ Comments: 1) six of the nine authors received honoraria from Medimmune or Schering -Plough; 2) the meta-analysis included unpublished data (and/or data from personal communications regarding ambiguities in the published data) from five of the seven included trials. (n = 540 patients), the use of a placebo-controlled design, and standard prescribed doses of commonly used dietary antioxidants, this study is the most important randomized clinical trial, to date, on the use of a supplemental antioxidant and radiation therapy. When reviewing the available literature on clinical data, a higher level of evidence is usually assigned to randomized controlled trials than to observational studies because this rigorous study design reduces bias through balancing the confounding properties of the comparator groups ( 46 ) . Several other studies have provided evidence that antioxidants can decrease the effectiveness of radiation therapy. For example, Ferreira et al. ( 6 ) randomly assigned 54 head and neck cancer patients who were undergoing radiation therapy to receive an oilbased oral rinse that contained either vitamin E or placebo before and after each daily dose of radiation. Although the vitamin E supplementation was associated with a 36% reduction in symptomatic mucositis, the authors also reported a decrease in 2-year overall survival (32% with supplemental vitamin E vs 63% with placebo; P = .13). This concerning decrease in overall survival, albeit not statistically signifi cant, may have been confounded by the greater percentage of patients with stage 3 and 4 tumors found in the vitamin E group. In another study, Lesperance et al. ( 14 ) investigated a historical cohort of 90 patients with nonmetastatic breast cancer who received conventional treatment (eg, surgery, chemotherapy, radiation therapy, and hormonal therapy) either alone or in combination with high doses of ␤ -carotene, vitamin C, niacin, selenium, coenzyme Q10, and/or zinc. Breast cancer -specifi c survival (ie, patients censored only at death from breast cancer) and disease-free survival were shorter in the nutrient-supplemented group than in the nonsupplemented group, but the differences were not statistically signifi cant (hazard ratio of breast cancer death = 1.75, 95% CI = 0.83 to 2.69, and hazard ratio of relapse = 1.55, 95% CI = 0.94 to 2.54, respectively). Despite the substantial limitations of these studies ( 6 , 14 ) , it is troubling that both reported results suggesting poorer survival with concurrent administration of antioxidants and cytotoxic therapy, even though these results are at odds with other studies. For example, two randomized trialsMisirlioglu et al. ( 39 ) , testing pentoxifylline and ␣ -tocopherol in patients with non -small cell lung cancer, and Lissoni et al. ( 41 ) , testing melatonin in patients with brain glioblastomas -found that radiotherapy combined with ␣ -tocopherol or melatonin supplementation increased survival. However, this suggestion of radiosensitization of tumors was not confi rmed by Berk et al. ( 42 ) in a randomized trial of radiation therapy and high-dose melatonin in brain metastases.
Despite concerns ( 8 ) about current recommendations supporting the use of antioxidant supplementation during oncological treatments, some antioxidants, such as amifostine (WR-2721), a thiol-containing antioxidant that has been approved by the Food and Drug Administration to increase the radioresistance of salivary gland tissues, show promise as cotherapies. Although some preclinical studies ( 47 -50 ) have shown that amifostine increases the radioresistance of tumors, neither the randomized clinical trials ( 51 -57 ) nor the meta-analyses (44,45) of this agent have provided conclusive evidence of increased radioresistance of tumors. This selective effect -of increasing radioresistance of normal tissues only -has been attributed to the preferential uptake of the active (ie, dephosphorylated) form of amifostine (WR-1065) into normal cells vs cancer cells ( 58 , 59 ) . It is not possible to know defi nitively, with the available data, whether amifostine increases radioresistance of tumors because the randomized clinical studies of amifostine have had brief follow-up, used variable doses and regimens, and based their sample sizes on estimates of the primary endpoints of toxicity (ie, mucositis and xerostomia) rather than on local tumor control. In a meta-analysis of amifostine studies, Mell et al. ( 44 ) stated that their " … results suggest that any effect of amifostine on reducing overall response [to radiation therapy], if it exists, is no larger than a 3% relative risk reduction. Assuming an expected overall response rate of 65%, this would correspond to a maximal risk difference no worse than approximately 2% (i.e., two fewer responses per 100 patients treated)." These authors further state that "These fi ndings, therefore do not support the hypothesis that amifostine has a clinically important tumor protective effect in these patients." Although many patients may accept the potential benefi ts of experiencing fewer treatment-related toxic effects (eg, xerostomia, mucositis) over the small risk of diminished tumor control (eg, 2 of 100 patients may fail treatment as a result of the tumor-protective effects of an adjunctive antioxidant), these possible concerns should be discussed with the patient before initiating amifostine.
Chemotherapy and Antioxidants
We also conducted a systematic search of the Medline database for all published randomized clinical trials of antioxidants and chemotherapy using the following key words: vitamins, antioxidants, chemotherapy, cancer, tumor control, side effects, and toxicity. We identified 16 randomized clinical trials that studied the concurrent use of antioxidant supplements and chemotherapy; 6 of those trials included a placebo control ( Table 3 ) . Although no decrements in tumor response rates or survival rates were observed in the studies that reported response data ( 71 , 72 ) , none of those studies were powered to evaluate these endpoints. For example, Pathak et al. ( 64 ) examined whether the concurrent administration of a high-dose antioxidant mixture containing vitamins C and E and ␤ -carotene with paclitaxel and cisplatin improved tumor response and survival in 136 patients with advanced non -small cell lung cancer and observed no survival or tumor response benefits with the antioxidants. However, the authors' conclusion that the antioxidant supplementation was safe is not warranted because the study was not sufficiently powered to evaluate a reduction in survival or tumor response. In a systematic review of the randomized trials of antioxidants and chemotherapy, Ladas et al. ( 76 ) found such a wide range of cancer diagnoses, chemotherapy regimens, and antioxidant supplementation that they could not draw definitive conclusions about the safety and efficacy of the antioxidant interventions.
Although several studies [reviewed by Mills et al. ( 77 )] have suggested that melatonin supplementation may improve the survival of chemotherapy-treated patients with some solid tumors, it is not clear that this effect is mediated exclusively by the antioxidant action of this hormone. For example, in a randomized clinical trial of cisplatin plus etoposide and melatonin, Lissoni et al. ( 66 ) observed improved tumor response rates in 100 patients with metastatic non -small-cell lung cancer. The same group of investigators ( 67 ) also observed similar results with melatonin in a study of 250 patients with various metastatic solid tumors who received several different chemotherapy regimens. These intriguing results should now be independently confi rmed in larger trials.
Future Directions
Numerous literature reviews ( 7 , 8 , 76 , 78 -86 ) have focused on the topic of whether supplemental antioxidants administered during chemotherapy or radiation therapy can protect normal tissues without adversely influencing tumor control. As noted above, variations in study design, intervention protocol, eligibility criteria, statistical power, timing of the observation or intervention, malignancy type, and anticancer regimens limit the ability of the authors of these reviews to make definitive conclusions regarding the risk of decreased tumor control as a consequence of administering supplemental antioxidants during chemotherapy and/or radiation therapy.
It is with this in mind that we fi nd it surprising that a recent review ( 85 , 86 ) defi nitively concludes that antioxidants (and other supplemental nutrients), when given concurrently with chemotherapy and/or radiation therapy, 1) do not interfere with chemotherapy and/or radiation therapy, 2) enhance the cytotoxic effects of chemotherapy and radiation therapy, 3) protect normal tissues, and 4) increase patient survival . In the concluding sentence of this review, the authors recommend that "Antioxidant and other nutrient food supplements are safe and can help to enhance cancer patient care" ( 86 ) . Such a recommendation merits close examination of the evidence because it is at odds with other authoritative reviews on this topic ( 7 , 76 , 78 , 80 , 84 ) . Of the 52 clinical studies Simone et al. ( 85 , 86 ) reviewed, 36 were observational, a study design that is limited by selection bias and unknown confounders. Of the 16 randomized controlled trials they reviewed, 10 included fewer than 50 patients, a sample size too small to inspire confidence in fi ndings of equivalent survival. Indeed, if antioxidant supplements interfered completely with an agent associated with an absolute increase in survival of 5%, a suitably powered trial would require approximately 2000 patients. The six remaining reports reviewed by Simone et al. ( 85 , 86 ) were randomized trials with at least 50 patients, and, of these, only one ( 89 ) tested an antioxidant. In this trial (n = 50), glutathione improved response rates and decreased neurotoxicity in advanced gastric cancer patients who received cisplatin. This is an interesting result, but it must be confi rmed in a larger study.
Importantly, many reports ( 39 -41 , 60 -72 , 79 ) provide a basis for continuing research on the potential for dietary and pharmaceutical antioxidants to enhance the effects of some cytotoxic regimens and/ or decrease toxicity without interfering with oncological actions. However, a more sophisticated recognition of the complexity and diversity of antioxidants is required when designing new studies. The profi le of antioxidant (ie, radical scavenging) and other (eg, on cell signaling and gene expression) actions of these compounds, as well as their differential bioavailability, distribution, metabolism, potency, and dynamic interrelationships, must be understood. In designing new trials of adjunctive treatments with antioxidants, consideration must be given to the specifi c chemotherapeutic agents and radiation therapy regimens and to the evaluation of appropriate intermediary biomarkers and clinical outcomes, including short-and long-term tumor control ( 84 ) . A challenge to these considerations is the absence of any consistent pattern of serum status of vitamins C and E, ␤ -carotene, or selenium in patients with cancer receiving chemotherapy ( 76 ) . It is noteworthy that although the initiation of anticancer therapies may lower plasma antioxidant concentrations by altering dietary intakes, an increase in plasma antioxidant levels has been associated with a reduction in the cancer burden ( 90 ) . It is important to consider results of research that Complete response rate higher in antioxidant patients vs no antioxidants ( P < .02) Increased partial response rate in antioxidant patients vs no antioxidants ( P < .01) Increased tumor regression rate (complete response and partial response) in antioxidant patients vs no antioxidants ( P < .001) Increased 1-y survival in antioxidant patients vs no antioxidants ( P < .001) Increased overall survival in antioxidant patients vs no antioxidants ( P < .05) Decreased neurotoxicity ( P < .05), thrombocytopenia ( P < .05), weight, myelosuppression ( P < .001), asthenia ( P < .001), cardiotoxicity ( P < .001), and stomatitis ( P < .05) in antioxidant patients vs no antioxidants ( No statistically significant differences in response or survival in antioxidant patients vs no antioxidants A trend toward decreased neurotoxicity in antioxidant patients vs no antioxidants Higher dose intensity in antioxidant patients vs no antioxidants * po = orally; IV = intravenous injection. addresses the effi cacy and safety of complementary therapy with high-dose antioxidant treatments in the context of the ongoing need for all patients to meet established dietary requirements for the essential vitamins C and E and the intake of carotenoids, fl avonoids, and related antioxidant phytochemicals ( 91 ) .
When a Potential for Harm Exists, Primum non nocere
Despite two decades of research on the concurrent use of antioxidants and chemotherapy or radiotherapy, the data remain insufficient to provide a clear guide for clinical practice. Much of the evidence to date regarding the effects of antioxidants on tumor control was derived from experimental research that has little relevance to patients, from observational studies that were confounded by known and unknown factors, and from clinical trials that lacked careful controls, adequate power, or accurate measures of tumor control. Further research is required to address these limitations and to more carefully consider the complexity of high-dose antioxidant interventions, including dose -response relationships, treatment timing and duration, and dynamic interrelationships with other antioxidants as well as with specific oncological therapies. New clinical investigations must identify appropriate patient populations, develop rational antioxidant doses and combinations, and establish well-defined intermediary biomarkers and clinical endpoints. Despite some intriguing studies ( 39 , 41 , 63 , 66 -75 ) that have suggested the benefit of adjunctive antioxidant treatments in cancer patients, the totality of the available evidence is equivocal at best and leaves us with serious concerns about the potential for harm. Our view on the use of complementary antioxidant therapy with chemotherapy or radiation therapy can be summarized in the following two points. First, data from a limited number of randomized controlled trials have shown that high-dose antioxidant supplementation during radiotherapy decreases local tumor control and shortens the survival of cancer patients. Although the potential for harm from this adjunctive therapy may be limited to a few antioxidants, the uncertainty about what doses and which compounds are clearly safe demands that high doses of any antioxidant should be avoided during radiation therapy unless clear evidence is available that the benefi ts outweigh the potential risk. Second, limited data and theoretical understanding regarding the mechanisms of action of dietary antioxidants suggest that at high doses, some of these compounds, alone or in combination, may enhance the effects of some cytotoxic regimens and/or decrease their toxicity without reducing oncological effi cacy. As such, continuing research on the use of concurrent supplemental antioxidants with chemotherapy and/or radiation therapy is warranted.
